| Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial G Wittert, K Bracken, KP Robledo, M Grossmann, BB Yeap, ... The lancet Diabetes & endocrinology 9 (1), 32-45, 2021 | 230 | 2021 |
| Testosterone therapy to prevent type 2 diabetes mellitus in at‐risk men (T4DM): design and implementation of a double‐blind randomized controlled trial G Wittert, E Atlantis, C Allan, K Bracken, A Conway, M Daniel, V Gebski, ... Diabetes, Obesity and Metabolism 21 (4), 772-780, 2019 | 40 | 2019 |
| Effect of testosterone treatment on bone microarchitecture and bone mineral density in men: a 2-year RCT M Ng Tang Fui, R Hoermann, K Bracken, DJ Handelsman, WJ Inder, ... The Journal of Clinical Endocrinology & Metabolism 106 (8), e3143-e3158, 2021 | 33 | 2021 |
| Recruitment strategies in randomised controlled trials of men aged 50 years and older: a systematic review K Bracken, L Askie, AC Keech, W Hague, G Wittert BMJ open 9 (4), e025580, 2019 | 32 | 2019 |
| Recruitment of men to a multi-centre diabetes prevention trial: an evaluation of traditional and online promotional strategies K Bracken, W Hague, A Keech, A Conway, DJ Handelsman, ... Trials 20, 1-14, 2019 | 20 | 2019 |
| Recovery of male reproductive endocrine function after ceasing prolonged testosterone undecanoate injections DJ Handelsman, R Desai, AJ Conway, N Shankara-Narayana, ... European journal of endocrinology 186 (3), 307-318, 2022 | 12 | 2022 |
| Telephone call reminders did not increase screening uptake more than SMS reminders: a recruitment study within a trial K Bracken, A Keech, W Hague, A Kirby, KP Robledo, C Allan, A Conway, ... Journal of clinical epidemiology 112, 45-52, 2019 | 8 | 2019 |
| Mediation analysis of the testosterone treatment effect to prevent type 2 diabetes in the Testosterone for Prevention of Type 2 Diabetes Mellitus trial KP Robledo, IC Marschner, DJ Handelsman, K Bracken, BGA Stuckey, ... European journal of endocrinology 189 (1), 50-57, 2023 | 5 | 2023 |
| 274-OR: effect of testosterone treatment on type 2 diabetes incidence in high-risk men enrolled in a lifestyle program: a two-year randomized placebo-controlled trial GA Wittert, KP Robledo, M Grossmann, K Bracken, BB Yeap, ... Diabetes 69 (Supplement_1), 2020 | 4 | 2020 |
| Strategies to improve adherence to skin self-examination and other self-management practices in people at high risk of melanoma: a scoping review of randomized clinical trials DM Ackermann, K Bracken, M Janda, RM Turner, JK Hersch, D Drabarek, ... JAMA dermatology, 2023 | 3 | 2023 |
| A high-volume, low-cost approach to participant screening and enrolment: Experiences from the T4DM diabetes prevention trial K Bracken, A Keech, W Hague, C Allan, A Conway, M Daniel, V Gebski, ... Clinical Trials 16 (6), 589-598, 2019 | 3 | 2019 |
| Long-term Outcomes of Testosterone Treatment in Men: A T4DM Postrandomization Observational Follow-up Study DJ Handelsman, M Grossmann, BB Yeap, BGA Stuckey, ... The Journal of Clinical Endocrinology & Metabolism 109 (1), e25-e31, 2024 | 2 | 2024 |
| DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostate—A randomized phase III double-blind, placebo … T Niazi, S Williams, ID Davis, MR Stockler, AJ Martin, W Hague, ... Journal of Clinical Oncology 38 (6_suppl), TPS385-TPS385, 2020 | 2 | 2020 |
| Testosterone for type 2 diabetes prevention in men: A 2-year multicentre, randomised, double-blind, placebo-controlled trial GA Wittert, E Atlantis, M Grossmann, BB Yeap, A Conway, B Stuckey, ... Clinical Endocrinology, 47-48, 2018 | 2 | 2018 |
| Using the Behaviour Change Wheel to identify barriers and targeted strategies to improve adherence in randomised clinical trials: The example of MEL-SELF trial of patient-led … DM Ackermann, JK Hersch, M Janda, K Bracken, RM Turner, KJL Bell Contemporary Clinical Trials 140, 107513, 2024 | 1 | 2024 |
| The use of linked administrative data in Australian randomised controlled trials: A scoping review S Fahridin, N Agarwal, K Bracken, S Law, RL Morton Clinical Trials, 17407745231225618, 2024 | 1 | 2024 |
| The importance of NOT being Other: Time to address the invisibility of nuanced gender and sexuality in clinical trials ADN Williams, K Hood, K Bracken, GW Shorter Trials 24 (1), 242, 2023 | 1 | 2023 |
| DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)—A randomized phase 3, double-blind, placebo-controlled trial … T Niazi, SM McBride, S Williams, ID Davis, MR Stockler, AJ Martin, ... Journal of Clinical Oncology 40 (16_suppl), TPS5103-TPS5103, 2022 | 1 | 2022 |
| Efficacy and safety of pentosan polysulfate sodium in people with symptomatic knee osteoarthritis and dyslipidaemia: protocol of the MaRVeL trial MAB Siddiq, X Liu, T Fedorova, K Bracken, S Virk, V Venkatesha, ... BMJ open 14 (5), e083046, 2024 | | 2024 |
| Testosterone Treatment, Weight Loss, and Health-related Quality of Life and Psychosocial Function in Men: A 2-year Randomized Controlled Trial M Grossmann, KP Robledo, M Daniel, DJ Handelsman, WJ Inder, ... The Journal of Clinical Endocrinology & Metabolism, dgae085, 2024 | | 2024 |
